BeOne Medicines Ltd. (06160) HKEX Company Information Sheet: Waivers, Exemptions, Depositary Agreement, and Regulatory Compliance Overview

BeOne Medicines Ltd: Key Waivers, Regulatory Exemptions, and Shareholder Considerations

Summary of Major Points for Investors

BeOne Medicines Ltd (Stock code: 06160) has published a detailed Company Information Sheet outlining numerous waivers, exemptions, and regulatory specifics following its listing on the Hong Kong Stock Exchange (HKEX) and its continuation as a Swiss corporation. This summary provides an in-depth look at the material points that could have significant implications for shareholders and potentially affect the company’s share price.

1. Dual Listing and Regulatory Regime

BeOne Medicines is dual-listed on HKEX and Nasdaq, and incorporated in Switzerland as of May 27, 2025. This unique regulatory structure means it is subject to Swiss law, U.S. securities regulations, and HKEX Listing Rules. The company has requested and received numerous waivers to avoid duplicative or conflicting requirements.
Key Shareholder Rights: Adjustments to shareholder meeting procedures, voting thresholds, and special resolutions now align more closely with Swiss and U.S. standards than with legacy HKEX requirements.

2. Waivers and Exemptions – What Investors Need to Know

BeOne Medicines has obtained critical waivers from strict compliance with HKEX Listing Rules and related ordinances, including:

Use of US GAAP for Financial Reporting: Financial statements will continue to be prepared under U.S. GAAP instead of HKFRS or IFRS. The company must provide reconciliations to IFRS and disclose key differences, but this could impact financial comparability with other HKEX-listed companies.
Connected Person Placing Authorizations: The company can issue shares to certain connected persons (notably, large shareholders like Baker Bros. Advisors LP and Hillhouse Capital Management) in certain circumstances without separate independent shareholder approval, provided specific conditions are met. This could affect dilution risk and the balance of power among shareholders.
Share Option Scheme Pricing: Options may be priced with reference to the higher of the Nasdaq closing price or the average of the last five Nasdaq trading days. This may result in option pricing that diverges from HKEX market prices and could influence employee incentives and dilution.
Collaboration Agreements: Waivers granted for collaboration agreements include not setting fixed terms or monetary caps due to the unpredictable nature of biotech commercialization. Potentially, this provides greater flexibility for business growth but also introduces uncertainty about future costs and revenues.
RMB Shares Not Listed on HKEX: The company issued RMB shares listed on the Shanghai STAR Market, which will not be listed on HKEX. This creates two classes of shares with different listing venues, and waivers were granted to accommodate this. Investors should be aware of possible liquidity and regulatory arbitrage between the two markets.
Corporate Communication, Securities Registration, and Transfer Requirements: Waivers allow for different standards for RMB shares on the STAR Market, including electronic-only communications and different transfer certification requirements.

3. Swiss Law Implications for Shareholder Protections

Major Corporate Actions: Amendments to share classes, constitutional documents, or voluntary dissolution require a two-thirds majority of votes present at general meetings, rather than the HKEX’s traditional three-fourths threshold. This slightly lowers the bar for passing major changes, which could be material in takeover or restructuring scenarios.
Voting and Meeting Procedures: Dual-majority voting and flexible meeting notice periods are codified in the Articles, following Swiss and U.S. norms. Shareholder ability to requisition meetings and propose director changes is enhanced, but with different thresholds and procedures compared to pure HKEX standards.
Auditor Appointment and Removal: Shareholders reserve the sole right to appoint and remove auditors; remuneration may be set by shareholders or, in some cases, delegated to the board.
Inspection of Register: Shareholders have inspection rights over the branch register in Hong Kong, subject to payment of a reasonable fee.

4. Taxation Highlights

Swiss Withholding and Income Tax: Swiss residents are subject to personal or corporate income tax on distributions. Non-residents, including Hong Kong and U.S. investors, may face Swiss withholding tax subject to applicable treaties.
U.S. Tax Implications: U.S. shareholders should be alert to Controlled Foreign Corporation (CFC) and Passive Foreign Investment Company (PFIC) rules, which could result in penalty taxes, loss of basis step-up, and additional reporting requirements (e.g., IRS Form 5471).
PRC Tax Risks: If BeOne is deemed a PRC tax resident, distributions and gains could be taxed in China, with withholding up to 20% for non-resident individuals.

5. Other Material Investor Considerations

Shareholder Voting Restrictions: The Articles and Swiss law now allow for dual-majority voting, meaning interested (connected) shareholders’ votes can be disregarded when required by HKEX rules, protecting minority interests.
Share Repurchases: Repurchases may be conducted by agreement with shareholders, subject to board approval and applicable law, and are also governed by Hong Kong’s Codes on Takeovers and Mergers and Share Repurchases.
Proxy Voting and Information Disclosure: Even though not all HKEX proxy and disclosure requirements are mirrored in the Articles, the company undertakes to provide equivalent protections through alternative mechanisms.
Potential for Shareholder Dilution: Waivers related to connected person placings and share issuance mandates may result in dilution if exercised extensively.

Potential Share Price Implications

Investors should closely watch:

Flexibility in capital raising – The company’s ability to issue shares to key connected investors without further independent approval could lead to rapid capital raises or dilution events.
Cross-border share structure – The existence of RMB shares not listed on HKEX may create market segmentation and potential arbitrage opportunities or risks.
Regulatory waivers – While these reduce compliance costs and enhance flexibility, they also introduce uncertainties and may lead to governance or shareholder protection risks not typical for HKEX-listed companies.
Tax regime complexity – Shareholders, especially those in the U.S. and China, face heightened tax planning considerations.

Any material change in these areas—such as regulatory review, major capital raising, or changes in tax/residency status—could have a significant impact on the company’s valuation and share price.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should consult their financial, tax, and legal advisors before making any investment decisions. The information is based on publicly available filings and may be subject to change. The author assumes no responsibility or liability for any errors or omissions or for any actions taken based on this information.

BeOne Medicines Ltd：主要豁免、監管寬免及股東需知要點

投資者必須關注的重點

BeOne Medicines Ltd（股份代號：06160） 公佈了公司資料表，詳細列出其於香港聯交所（HKEX）上市及轉為瑞士公司後，獲批的重要豁免、寬免及監管細節。以下為可能影響股東權益及股價的重要資訊。

1. 雙重上市及監管框架

BeOne Medicines現於HKEX及納斯達克雙重上市，並於2025年5月27日註冊為瑞士公司。 公司受瑞士法律、美國證券法及香港上市規則多重監管，故申請多項豁免以避免重複或衝突的規定。
股東權益調整： 股東大會程序、表決門檻及特別決議等已更貼近瑞士及美國規範，而非傳統港交所標準。

2. 豁免及寬免——投資者需留意事項

財務報告採用美國會計準則（US GAAP）： 公司將繼續以US GAAP編製財務報表，而非HKFRS或IFRS，並需提供與IFRS的調節及主要差異。這可能影響與其他港股公司的財報可比性。
關連人士配售授權： 公司可在特定情況下向重要股東（如Baker Bros. Advisors LP、Hillhouse Capital等）配售股份，無需獨立股東批准，但需符合作出之條件。此舉可能影響攤薄風險及股東權力分布。
股票期權定價： 期權可參考納斯達克收市價或連續五日平均收市價（取較高者）定價，可能與港股市場價有差距，影響員工激勵及攤薄程度。
合作協議的靈活性： 豁免合作協議設固定期限及金額上限，反映生物科技商業化難以預測，有利業務發展但同時帶來收入成本不確定性。
人民幣股份（RMB Shares）不在港交所上市： 公司發行並於上海科創板上市的人民幣股份，與港股屬同類股份但未在港交所掛牌，造成兩地市場分割，並獲相關豁免。投資者需關注兩地流動性及監管套利風險。
公司通訊、登記及過戶要求： 人民幣股份於科創板可只用電子通訊及不同過戶認證標準。

3. 瑞士法例對股東保障的影響

重大公司行動： 股份類別變更、章程修訂或自願清盤，需出席股東大會三分之二多數通過，較港交所傳統四分之三略低，於收購或重組時或有影響。
會議及表決程序： 採用雙重多數表決，會議通知期更具彈性，與瑞士及美國慣例一致。股東可提議召開會議及更換董事，但程序及門檻與港交所有所不同。
核數師任免： 由股東大會決定核數師任免，酬金可由股東或授權董事會決定。
查閱登記冊： 股東可付合理費用查閱香港分冊。

4. 稅務重點

瑞士稅務： 瑞士居民須就分派收入繳稅，非居民如香港及美國投資者則或需受瑞士預扣稅影響，視乎雙邊稅務協定。
美國稅務風險： 美國股東應留意CFC及PFIC條例，或需繳付懲罰性稅項、失去遺產基礎調整及額外申報（如IRS 5471表格）。
中國內地稅務： 如公司被視為中國稅務居民，派息及資本收益或受最高20%預扣稅。

5. 其他重要投資者事項

投票權限制： 現行章程及瑞士法例容許雙重多數投票，於需要時可不計相關人士（關連股東）之投票，保障小股東利益。
股份回購： 經董事會批准後可與股東協議回購，受香港收購及股份回購守則監管。
委託投票及資訊披露： 雖並非所有港交所規定於章程中反映，公司承諾以其他方式提供同等保障。
潛在攤薄風險： 關連人士配售及新股發行授權若被大量行使，或對現有股東造成攤薄。

潛在股價影響

投資者需密切關注：

集資靈活性： 公司可向關連股東快速配售股份，或帶來集資及攤薄風險。
跨市場股份結構： 人民幣股份不在港上市，可能出現市場分割及套利機會或風險。
監管豁免： 減少合規成本及提升靈活性，但或帶來治理或股東保障風險。
稅務複雜性： 尤其美國及內地投資者需注意相關稅務規劃。

於以上範疇出現重大變動（如監管審查、大型集資、稅務或居籍變動），皆可對公司估值及股價構成重大影響。

免責聲明

本文僅供參考，不構成任何投資建議。投資者應於作出任何投資決定前諮詢財務、稅務及法律顧問。本文資料源自公開文件，或會更新或更改。作者對任何錯漏或根據此資訊作出的行動不承擔任何責任。